NEW YORK (GenomeWeb News) — The National Cancer Institute wants to fund scientists aiming to develop novel ideas and technologies that use molecular or cellular analysis in cancer detection and risk assessment, and will support them with up to $500,000.
Under the Innovative Molecular Analysis Technologies program, NCI plans to grant up to $3 million in fiscal 2010 to support as many as ten investigators studying “exceptionally innovative, high risk, original and/or unconventional exploratory research that potentially could help create new scientific paradigms or overcome barriers in cancer research.”
This IMAT program will fund investigators with R21 grants for exploratory pilot projects over a three-year period with no more than $200,000 per year.
The goal of these grants is to fuel promising research into concepts and ideas that are early in the development stages in several areas that NCI has identified as strategic priorities. The institute wants new technologies for early detection of cancer and risk assessment, analytical technologies with potential clinical utility, and technologies for analyzing cancer at the cellular and molecular levels.
These could include technologies for genomic, proteomic, or epigenomic biomarker detection technologies, cellular imaging technologies, and point-of-care related devices such as microfluidics or nanotechnology tools.
They also could include ‘omics tools for predicting or monitoring patient response, genotyping technologies, high-throughput screening or biosensor technologies, and pharmacogenomic and toxicogenomic tools, among others.
More information about the Innovative Technology Development for Cancer Research program may be found on the National Institutes of Health’s website.